---
provider: claude_code
model: claude-sonnet-5-5
cached: false
start_time: '2026-10-15T20:02:11.198696'
end_time: '2026-10-15T20:04:35.952511'
duration_seconds: 144.75
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Long QT Syndrome 1
  mondo_id: MONDO:0100316
  category: Mendelian
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-sonnet-5-5
  num_turns: 1
  total_cost_usd: 0.8085
  session_id: 1411d6e0-a3a9-57ef-a642-a756ff0785bd
  stop_reason: end_turn
  assistant_text_blocks: 1
reference_validation:
  total_references: 16
  verified: 16
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 16
  on_topic: 7
  off_topic: 2
  off_topic_references:
  - PMID:8900284
  - PMID:9140400
  needs_review: true
  validator_version: 0.3.0
term_validation:
  total_terms: 30
  verified: 29
  not_found: 0
  obsolete: 0
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 19
  labels_matching: 9
  labels_mismatched: 4
  mislabelled_terms:
  - term_id: MONDO:0100316
    reported_labels:
    - given in the template; confirm the label
    ontology_label: long QT syndrome 1
  - term_id: HP:0001279
    reported_labels:
    - Syncope (often exertional or emotion-triggered)
    ontology_label: Syncope
  - term_id: HP:0001250
    reported_labels:
    - Seizure (misdiagnosed arrhythmic syncope)
    ontology_label: Seizure
  - term_id: CHEBI:7445
    reported_labels:
    - 'Nonselective agents: nadolol'
    ontology_label: nafarelin
  labels_variant: 6
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Long QT Syndrome 1
- **MONDO ID:** MONDO:0100316 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Long QT Syndrome 1** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Research Report: Long QT Syndrome 1 (LQT1; KCNQ1-related Romano-Ward syndrome)

## How to use this report

- **Provenance.** I wrote this from background knowledge. No web, PubMed or ontology lookups were run, and no abstracts were fetched. For the dismech KB, treat every PMID and CURIE as a lead.
- **PMIDs.**
  - Marked **[v]**: I am fairly confident of the PMID.
  - Marked **[?]**: the paper is real but I am not sure of the PMID. Run `just fetch-reference PMID:<id>` and check the title before use.
  - Uncited statements come from general knowledge, such as GeneReviews, the ESC/HRS guidelines and textbook cardiology.
- **No verbatim quotes.** Snippets must be copied from the cached reference body, so I give none. Fetch each reference first.
- **CURIEs.** HP, GO, CL, UBERON, CHEBI, NCIT and HGNC identifiers were written from memory. Per repository policy, run `just validate-terms` and `runoak` lookups before binding. Treat any unresolved one as unbound.
- **GeneReviews.** The chapter "Long QT Syndrome" (Ackerman, NBK1129) is the expected Mendelian baseline. Run `just check-genereviews` to confirm.

---

## 1. Disease Information

**Overview.** LQT1 is the most common genetic subtype of congenital long QT syndrome (LQTS). It is a cardiac channelopathy caused by heterozygous loss of function of KCNQ1. KCNQ1 encodes Kv7.1, the pore-forming α-subunit of the slow delayed-rectifier K⁺ current (I_Ks).
- The delayed ventricular repolarization shows on the ECG as a prolonged QT interval, typically with broad-based T waves.
- It predisposes to syncope, polymorphic ventricular tachycardia (torsade de pointes, TdP), ventricular fibrillation and sudden cardiac death (SCD).
- Events are classically adrenergically triggered, especially by exercise, with swimming as the signature trigger.
- Biallelic KCNQ1 loss causes Jervell and Lange-Nielsen syndrome (JLNS1): severe LQTS plus congenital sensorineural deafness.

**Identifiers** (verify all):

| Source | Identifier |
|---|---|
| MONDO | MONDO:0100316 (given in the template; confirm the label) |
| OMIM | #192500 (LQT1); #220400 (JLNS1); gene *607542 |
| ICD-10-CM | I45.81 (long QT syndrome) |
| MeSH | Long QT Syndrome (D008133) |
| Orphanet | Romano-Ward syndrome (ORPHA:101016) is the umbrella entry. Look up LQT1-specific entries. |
| Gene | KCNQ1, hgnc:6294 (repo lowercase form), NCBI Gene 3784, UniProt P51787, 11p15.5 |

**Synonyms.** LQT1; Romano-Ward syndrome type 1; KCNQ1-related long QT syndrome; KVLQT1-related LQTS; long QT syndrome type 1; autosomal dominant LQTS (KCNQ1). Older literature uses "KVLQT1".

**Data origin.** This is aggregated disease-level knowledge from family cohorts, registries (International LQTS Registry, Rochester NY) and curated resources. It is not EHR-derived.

**Lumping and splitting.**
- JLNS1 is the biallelic KCNQ1 phenotype. Decide whether it is a `has_subtypes` row on LQT1 or a separate entry with its own MONDO term.
- Genotype-specific LQTS is usually curated as separate Mendelian entries (LQT1, LQT2, LQT3). A "congenital long QT syndrome" `Grouping` is the natural covering record.

---

## 2. Etiology

**Causal factor.** Germline pathogenic variants in KCNQ1 (reduced I_Ks).
- ClinGen classifies KCNQ1 as a Definitive gene for LQTS (Adler et al. 2020, PMID:31983240 [v]).
- Discovery: Wang et al. 1996 (PMID:8589714 [v]) positionally cloned KVLQT1.
- Functional basis: Sanguinetti et al. 1996 (PMID:8900283 [v]) and Barhanin et al. 1996 (PMID:8900284 [v]) showed that KvLQT1 co-assembles with minK (KCNE1) to form I_Ks.

**Genetic risk and modifiers.**
- **Variant location and type.**
  - Missense variants in the transmembrane core and cytoplasmic loops carry higher risk than C-terminal variants.
  - Dominant-negative variants are more severe than haploinsufficient (truncating or non-trafficking) ones.
  - Sources: Moss et al. 2007, Circulation (PMID unverified [?]); Barsheshet et al. 2012, cytoplasmic loops [?]; Shimizu et al.
- **Modifier loci.**
  - Common variants at NOS1AP and other QT-interval GWAS loci modulate QTc and risk in LQTS (Tomás et al.; Crotti et al.). PMIDs [?].
  - Co-inherited second variants (compound or multiple mutations) worsen severity.
  - KCNE1 D85N is a common modifier.
- **Sex and age.**
  - Boys carry higher risk before puberty and women higher risk in adulthood, with postpartum a particular high-risk period.
  - This pattern is described across LQTS cohorts (Goldenberg/Moss). PMIDs [?].

**Environmental and acquired risk.** QT-prolonging drugs, hypokalemia, hypomagnesemia and bradycardia-inducing conditions add to the inherited reduction of repolarization reserve. See section 5.

**Protective factors.**
- Genotype-specific: C-terminal and haploinsufficient (non-dominant-negative) variants carry lower risk.
- Beta-blocker therapy (section 12) is protective.
- No well-established protective alleles are documented. Some reported common-variant effects at QT loci are likely modest.

**Gene-environment interactions.** The central interaction is between the inherited I_Ks deficit and sympathetic activation.
- Normally I_Ks rises with β-adrenergic stimulation and shortens the action potential at fast heart rates. In LQT1 this adaptive shortening fails.
- Triggers are therefore exercise, emotional stress and sudden arousal. Swimming and diving are classic triggers, probably through the combined diving reflex, face immersion and adrenergic surge. Ackerman et al. 1999 Mayo Clin Proc [?].
- Genotype-specific triggers: Schwartz et al. 2001, Circulation (PMID:11208699 [v]). LQT1 events cluster during exercise and emotional arousal, whereas LQT2 and LQT3 differ in trigger pattern.

---

## 3. Phenotypes

Frequencies below are qualitative or approximate. Fetch the cited cohorts for exact figures.

| Phenotype | Suggested HPO | Frequency / notes |
|---|---|---|
| Prolonged QT interval (QTc often 450–500 ms; broad-based T waves) | HP:0001657 | Very frequent. A substantial minority of genotype-positive carriers have QTc in the normal range (concealed LQTS), so penetrance is incomplete. |
| Syncope (often exertional or emotion-triggered) | HP:0001279 | Common in symptomatic probands. This is the main symptom. |
| Torsade de pointes / polymorphic VT | HP:0001664 / HP:0004756 | Mechanism of syncope and seizure-like events. |
| Ventricular fibrillation / cardiac arrest | HP:0001663 / HP:0001695 | Can be the first presentation. |
| Sudden cardiac death | HP:0001645 | Untreated risk is substantial. |
| Seizure (misdiagnosed arrhythmic syncope) | HP:0001250 | Occasionally mistaken for epilepsy. |
| Palpitations | HP:0001962 | Occasional. |
| Sinus bradycardia | HP:0001688 | Mild, more common in LQTS children. |
| Sensorineural hearing impairment | HP:0000407 | **JLNS1 only** (biallelic), congenital and profound. |

**Characteristics.**
- **Onset.** Childhood to adolescence is typical. Exercise-related events peak in school age, and some present in adulthood or by ECG screening.
- **Severity.** Variable, even within families (variable expressivity). Biallelic disease (JLNS1) is the most severe, with events in infancy.
- **Course.** Episodic arrhythmic events on a stable ECG phenotype. The risk is lifelong and modulated by age and sex.
- **Quality of life.** Constraints include sports restriction, medication adherence, ICD shocks, anxiety and depression, and school or career effects. QoL data are mostly from ICD cohorts (PMIDs not recalled).

---

## 4. Genetic/Molecular Information

- **Gene.** KCNQ1 (hgnc:6294), 11p15.5, 16 exons. The protein, Kv7.1, has 6 transmembrane segments (S1–S6), a pore (S5–S6) and a voltage sensor (S4). The C-terminus binds calmodulin, PIP2 and the AKAP9/Yotiao–PKA complex.
- **Variant classes.**
  - Missense (the majority), in-frame indels, frameshift and nonsense variants, splice variants, and exon-level deletions.
  - The spectrum was catalogued in Splawski et al. 2000 (PMID:10973849 [v]) and the Kapplinger et al. 2009 compendium (PMID:19716085 [?]).
- **Functional consequences.**
  - Loss of function by dominant-negative suppression of wild-type subunits in the tetramer. This gives a stronger reduction in I_Ks than haploinsufficiency.
  - Haploinsufficiency from trafficking defects or truncations.
  - Variants that impair β-adrenergic or PKA regulation, such as the Yotiao-binding region. Loss of the I_Ks response to sympathetic drive is a key LQT1 mechanism.
  - Variants that impair PIP2 interaction or calmodulin binding.
- **Population frequency.** Pathogenic LQT1 variants are individually rare. Interpret gnomAD allele frequencies with ClinGen/ACMG LQTS-specific guidance. Founder variants are listed in section 9.
- **Somatic or germline.** Germline. Somatic mosaicism is not an established feature.
- **Zygosity.** Heterozygous gives Romano-Ward LQT1. Homozygous or compound heterozygous gives JLNS1 (Neyroud et al. 1997, PMID:9140400 [v]).
- **Other genes in the LQTS family** (not LQT1): KCNH2 (LQT2), SCN5A (LQT3), CALM1/2/3, TRDN, CASQ2 and others. Adler 2020 retains only KCNQ1, KCNH2 and SCN5A as Definitive for typical LQTS.
- **Epigenetic or chromosomal.** Not a prominent feature. KCNQ1 lies in the imprinted 11p15.5 region, and the imprinted KCNQ1OT1 locus matters for Beckwith-Wiedemann syndrome. This does not drive LQT1. Large KCNQ1 deletions and duplications occur, so MLPA or CNV analysis is advised.

---

## 5. Environmental Information

- **QT-prolonging drugs.** Class IA/III antiarrhythmics, macrolides, fluoroquinolones, antipsychotics, ondansetron and others. Check CredibleMeds.
- **Electrolytes.** Hypokalemia and hypomagnesemia (diarrhea, diuretics, anorexia) increase risk.
- **Triggers.** Exercise, especially swimming and diving, sudden emotional stress, and loud noise (more LQT2).
- **Lifestyle.** Competitive sport has risk implications. See section 13.
- **Infectious agents.** None. Fever and illness act as physiologic stressors.

---

## 6. Mechanism / Pathophysiology

**Ordered causal chain**

1. A pathogenic KCNQ1 variant (heterozygous germline) produces a defective Kv7.1 α-subunit. The defect is a trafficking or gating failure, a dominant-negative effect, or truncation.
2. Mutant subunits co-assemble with wild-type Kv7.1 and KCNE1, **leading to** reduced I_Ks density. This is demonstrated in heterologous expression (Sanguinetti 1996, PMID:8900283; Barhanin 1996, PMID:8900284 [v]).
3. Reduced I_Ks lowers repolarization reserve, **leading to** prolonged ventricular action potential duration (APD) and QT interval. This is demonstrated by ECG and by patient-derived iPSC cardiomyocytes (Moretti et al. 2010, NEJM, PMID:20660394 [?]).
4. At baseline heart rate the APD prolongation is moderate. During sympathetic stimulation, normal I_Ks increases and shortens APD, but this response is **absent or blunted** in LQT1. Meanwhile β-adrenergic stimulation augments L-type Ca²⁺ current (I_CaL), **resulting in** exaggerated APD prolongation and transmural dispersion of repolarization at fast rates.
5. Prolonged APD allows L-type Ca²⁺ channel reactivation and spontaneous Ca²⁺ release, **leading to** early afterdepolarizations (EADs). Combined with dispersion of repolarization this creates the substrate for reentry.
6. EAD-triggered activity on the dispersed substrate **leads to** TdP. This is shown in the transgenic LQT1 rabbit (Brunner et al. 2008, J Clin Invest, PMID:18464931 [?]).
7. TdP **results in** syncope if self-terminating, or in ventricular fibrillation and sudden cardiac death if sustained.
8. **Branch (JLNS1).** Biallelic loss also removes KCNQ1/KCNE1 K⁺ secretion in the stria vascularis marginal cells. This reduces endolymph K⁺, **leading to** hair cell dysfunction and congenital deafness. Demonstrated in the Kcnq1 knockout mouse (Casimiro et al. 2001; Lee et al. 2000), with PMIDs [?]. KCNQ1 loss in the mouse also causes gastric hyperplasia.
9. **Inferred** (not directly shown in humans): the sympathetic-state dependence of events results from the combined I_Ks deficit and unchanged I_CaL augmentation. This is the working model, supported by gene-specific trigger data (Schwartz 2001, PMID:11208699).

**Suggested GO terms (verify):**
- delayed rectifier potassium channel activity (GO:0005251)
- regulation of ventricular cardiac muscle cell membrane repolarization (GO:0060307)
- cardiac muscle cell action potential involved in contraction (GO:0086002)
- voltage-gated potassium channel complex (GO:0008076)
- potassium ion transmembrane transport (GO:0071805)
- response to β-adrenergic stimulation (use an existing GO term after lookup)
- inner ear K⁺ homeostasis (JLNS branch; find the GO term)

**Modifier annotation.** In the dismech `modifier` slot, `DECREASED` fits "I_Ks current" quantitatively. `LOSS_OF_FUNCTION` and `functional_impact_category: DOMINANT_NEGATIVE` or `LOSS_OF_FUNCTION` apply to the variant. Choose per variant class.

**Immune and metabolic.** Not involved.

**Molecular profiling.** No consistent disease-specific signature. iPSC-CM models show reduced I_Ks and prolonged APD. Single-cell and spatial studies are not established for this disease.

**Cell types (CL).** Ventricular cardiac muscle cell (CL:0002131), cardiac muscle cell (CL:0000746), and for JLNS the marginal cell of the stria vascularis (look up the CL term).

---

## 7. Anatomical Structures Affected

- **Primary organ.** Heart, especially the ventricular myocardium (UBERON:0000948 heart; UBERON:0002082 cardiac ventricle). Structurally the heart is normal.
- **Secondary.**
  - Inner ear in JLNS1: the stria vascularis of the cochlea.
  - Other KCNQ1-expressing tissues (gastrointestinal, pancreas, kidney) are of uncertain clinical significance in LQT1.
- **Subcellular.** Sarcolemma (plasma membrane) of cardiomyocytes. Kv7.1 trafficking and the Yotiao/PKA macromolecular complex are involved.
- **Lateralization.** Not applicable. The disease is bilateral and global.

---

## 8. Temporal Development

- **Onset.** Congenital genetic condition. Symptoms occur from infancy (JLNS1) to adulthood. The usual symptomatic onset in LQT1 is school age.
- **Progression.** Non-degenerative. The ECG phenotype is stable, and risk varies with age, sex and exposure. Risk is highest at ages 5–15, then declines. In women it rises again in the postpartum period.
- **Pattern.** Episodic and trigger-linked (exercise, emotion).
- **Remission.** No remission. Risk is reduced by therapy.
- **Critical windows.** Childhood and adolescence (males), adulthood and postpartum (females).

---

## 9. Inheritance and Population

- **Epidemiology.**
  - Overall LQTS prevalence is about 1 in 2,000 live births by neonatal ECG screening (Schwartz et al. 2009, Circulation, PMID:19841300 [v]).
  - LQT1 accounts for roughly one third of genotyped LQTS, with LQT2 slightly lower and LQT3 about 5–10%.
  - JLNS1 is rare (about 1–6 per million in most populations, higher in Norway).
- **Inheritance.**
  - Romano-Ward LQT1: autosomal dominant (HP:0000006).
  - JLNS1: autosomal recessive (HP:0000007).
  - Incomplete penetrance (HP:0003829) and variable expressivity (HP:0003828).
  - Germline mosaicism and anticipation: not features.
- **Founder effects.**
  - Finland has several KCNQ1 founder variants (e.g., G589D, IVS7-2A>G).
  - Norway and Sweden have KCNQ1 R518X and Y111C in JLNS cohorts (Neyroud 1997 and later Scandinavian studies).
  - South Africa has KCNQ1 A341V, the Afrikaner founder variant associated with severe disease (Brink et al. 2005, Circulation [?]).
- **Consanguinity.** Relevant to JLNS1 (autosomal recessive).
- **Demographics.** No strong ethnic predisposition for typical LQT1 beyond founder effects. The sex ratio is about equal for variant carriers, but events are more frequent in males in childhood and females in adulthood. Age: see section 8.
- **Carrier frequency.** Pathogenic KCNQ1 variants in the general population are about 1 in 1,000–2,000 (from LQTS prevalence). Use gnomAD for refined estimates.

---

## 10. Diagnostics

- **ECG.**
  - Resting 12-lead ECG with QTc (Bazett, or Fridericia at high heart rates). The typical LQT1 T wave is broad-based, with onset of T early after the ST segment.
  - Exercise testing shows QTc failing to shorten, or lengthening, in recovery (Sy et al. 2011 [?]).
  - Epinephrine provocation (Shimizu) causes paradoxical QT prolongation in LQT1. It is less used now.
- **Holter monitoring.** For T-wave alternans and TdP.
- **Clinical criteria.**
  - The Schwartz score is ≥3.5 for high probability. Original Schwartz and Crotti: PMID [?].
  - 2022 ESC guidelines (PMID:36017572 [v]) set LQTS diagnosis as QTc ≥480 ms on repeated ECGs, or Schwartz score >3, or a pathogenic variant.
  - 2015 ESC guidelines: PMID:26320108 [v].
- **Genetic testing.** Strongly recommended for clinically diagnosed LQTS (Class I) and for cascade testing of relatives (HRS/EHRA consensus: PMID:21787999 [?]; 2013 update PMID:24011539 [?]).
  - Use a multi-gene panel including KCNQ1, KCNH2 and SCN5A, with at least CNV analysis (MLPA or NGS-CNV) for KCNQ1.
  - Yield is about 75–80% in clear clinical LQTS.
  - WES and WGS are not first-line for a classic case. Panel analysis is preferred.
  - Use ClinGen Variant Curation Expert Panel and ACMG/AMP criteria for classification.
- **Differential diagnosis.** Acquired QT prolongation (drugs, electrolytes), LQT2/LQT3 and other genotypes, CPVT, Brugada syndrome, short QT syndrome, epilepsy, vasovagal syncope, Timothy syndrome, Andersen–Tawil syndrome.
- **Screening.**
  - Cascade family testing is the most effective approach.
  - Neonatal ECG screening was studied in Italy (Schwartz 2009, PMID:19841300) but is not standard in most countries.
- **Biomarkers or imaging.** None specific. Echocardiography is typically normal. JLNS1 diagnosis uses audiometry.

---

## 11. Outcome/Prognosis

- **Untreated.** Substantial risk of syncope, cardiac arrest and SCD. Historical series (Moss et al. 1985 [?]; Schwartz et al.) reported about 20% first-year mortality after a first syncope in symptomatic LQTS.
- **Treated.** Beta-blockade markedly lowers event rates in LQT1, and LQT1 is the genotype with the best response (Moss et al. 2000 [?]; Priori et al. 2004 JAMA, PMID:15367556 [?]).
- **Prognostic factors.**
  - Prior syncope or cardiac arrest.
  - QTc >500 ms.
  - Transmembrane or cytoplasmic loop location and dominant-negative function (Moss 2007; Barsheshet 2012; PMIDs [?]).
  - Age and sex (see section 8).
  - Non-adherence to beta-blockers or QT-prolonging drug exposure.
  - Risk calculators: the 1-2-3 LQTS-Risk model (Mazzanti et al. 2018, JACC) [?].
- **Risk stratification.** Priori et al. 2003, NEJM [?], is the classic genotype-based approach.
- **JLNS1.** Worse prognosis despite therapy, with high event rates. Beta-blockers are often insufficient, and the ICD and sympathetic denervation are used more often.
- **Quality of life.** See section 3.

---

## 12. Treatment

**Therapy ladder (ESC 2022, HRS/EHRA).**

1. **Lifestyle.**
   - Avoid QT-prolonging drugs and treat electrolyte disturbance.
   - Avoid unsupervised swimming. Exercise restrictions are now individualized by shared decision-making (Johnson and Ackerman 2013, Br J Sports Med [?]).
2. **Beta-blockers.**
   - Nonselective agents: nadolol (CHEBI:7445) and propranolol (CHEBI:8499) are preferred.
   - Metoprolol is less effective. Nadolol has been shown superior to others (Chockalingam et al. 2012 [?]).
   - Use for all clinically affected patients, and often for genotype-positive patients with normal QTc.
   - NCIT: Pharmacotherapy (NCIT:C15986), with `therapeutic_agent` bound to CHEBI. `therapeutic_modality: SMALL_MOLECULE`.
3. **Left cardiac sympathetic denervation (LCSD).**
   - For breakthrough events on beta-blockers or when beta-blockers are not tolerated (Schwartz et al. 2004, Circulation [?]).
   - NCIT: Surgical Procedure (NCIT:C15329) with `preferred_term` "left cardiac sympathetic denervation". `therapeutic_modality: SURGERY`.
4. **ICD.**
   - For survivors of cardiac arrest, and for recurrent syncope or arrhythmia despite therapy.
   - Treat as a device. Per repo convention, use the surgical NCIT action term with a medical-device qualifier.
   - Complications include inappropriate shocks, lead problems and psychological burden.
5. **Experimental or investigational.**
   - Mexiletine and ranolazine are mainly for LQT3, with limited LQT1 data.
   - I_Ks activators (e.g., ML277), gene therapy, and KCNQ1 gene replacement or editing are preclinical. No verified NCT identifiers were found. Search ClinicalTrials.gov before adding a `clinical_trials` row.
6. **Pharmacogenomics.** No genotype-guided drug dosing is standard. CYP2D6 affects propranolol and metoprolol exposure. Check CPIC.
7. **Side effects.** Beta-blocker fatigue, bronchospasm, bradycardia and mood effects. Abrupt withdrawal is dangerous.

---

## 13. Prevention

- **Primary.** Not applicable, since the condition is genetic. Reproductive options include genetic counseling and PGT.
- **Secondary.**
  - Cascade genetic testing and ECG of first-degree relatives, with early beta-blocker therapy for carriers.
  - Neonatal ECG screening is under study.
- **Tertiary.**
  - Lifelong beta-blockade, drug-avoidance lists, electrolyte repletion during illness, and AED availability.
  - Family and school education, and exercise counseling.
- **Counseling.** NSGC, ACMG and GeneReviews guidance. In JLNS1, carrier parents are heterozygous and may themselves have mild LQT1.
- **Special periods.** Postpartum monitoring, with beta-blockers continued in pregnancy.

---

## 14. Other Species / Natural Disease

- Natural KCNQ1-related disease is not well established in non-human species.
- I did not find, and could not verify, a defined OMIA entry for LQT1 in companion animals. Check OMIA (`KCNQ1`) before asserting any.
- KCNQ1 is highly conserved across vertebrates. Orthologs: mouse Kcnq1 (MGI), zebrafish kcnq1. Look up NCBI Gene IDs.
- No zoonotic or transmission aspects apply.

---

## 15. Model Organisms

- **Mouse.**
  - Kcnq1 knockout mice show deafness, vestibular defects and gastric hyperplasia (Lee et al. 2000, J Clin Invest [?]), and a JLNS1-like phenotype (Casimiro et al. 2001, PNAS [?]).
  - **Limitation.** Mouse ventricular repolarization is dominated by other currents (I_to, I_Kur), and I_Ks plays a minor role at mouse heart rates. Murine QT prolongation is therefore a poor proxy.
  - Suggested KB treatment: `animal_models` linked via `modeled_mechanisms` to the stria vascularis and I_Ks nodes. Add a `SPECIES_MISMATCH` divergence for the cardiac repolarization node, or `PARTIALLY_RECAPITULATES` with `LOW` fidelity.
- **Rabbit.** Transgenic LQT1 rabbits (dominant-negative KCNQ1-Y315S) show prolonged QT, EADs and spontaneous TdP/SCD (Brunner 2008, PMID:18464931 [?]). Rabbit repolarization is closer to human, so fidelity is `HIGH` for the cardiac nodes.
- **Guinea pig and canine.** Pharmacologic I_Ks block models in whole heart and wedge preparations.
- **Human iPSC-cardiomyocytes.** Patient-derived LQT1 iPSC-CMs show prolonged APD and reduced I_Ks (Moretti 2010, NEJM [?]). Classified as `IN_VITRO` and a good platform for drug testing.
- **Heterologous expression** (Xenopus oocytes, CHO/HEK): the basis for variant functional classification (Sanguinetti 1996).
- **Resources.** MGI, ZFIN, IMPC, Alliance of Genome Resources.

---

## Suggested KB entry (summary)

- **Disease class.** Mendelian; autosomal dominant with reduced penetrance; `inheritance_term` HP:0000006.
- **Genetic.** KCNQ1 (hgnc:6294), `relationship_type: CAUSATIVE`. Record ClinGen validity by copying the CGGV record. Do not assign a tier.
- **Pathophysiology nodes, as a chain:**
  - KCNQ1 loss of function
  - Reduced I_Ks and repolarization reserve
  - Failure of sympathetic-driven APD shortening
  - APD/QT prolongation
  - EADs and dispersion of repolarization
  - Torsade de pointes
  - Syncope and sudden cardiac death
  - Optional branch: stria vascularis K⁺ secretion failure leading to deafness (JLNS1 subtype)
- **Environment.** Exercise/swimming, emotional stress and QT-prolonging drugs, via `influences_mechanisms` with `TRIGGERS` or `EXACERBATES`.
- **Treatment.** Nadolol and propranolol (`SMALL_MOLECULE`), LCSD (`SURGERY`) and ICD, plus an experimental IKs-activator or gene-therapy gap.
- **Discussions.** A `HUMAN_MODEL_MISMATCH` for the mouse Kcnq1 model, with mouse versus rabbit versus human repolarization as the open question.

## Gaps and verification worklist

1. Fetch and verify every **[?]** PMID. Do not use one that fails to match the title.
2. Pull exact frequencies for phenotypes (syncope, concealed LQTS, cardiac arrest) from the International LQTS Registry papers.
3. Verify all CURIEs with `just validate-terms` (HP, GO, CL, UBERON, CHEBI, NCIT, hgnc).
4. Search ClinicalTrials.gov for LQT1-specific trials (none verified here).
5. Confirm MONDO:0100316 label and decide the LQT1/JLNS1 lump-or-split with `mapping-analysis` and `disease-classification`.
6. Check OMIA for any natural animal disease before filling section 14.

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 16 |
| Resolved | 16 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 16 |
| On topic | 7 |
| Off topic | 2 |

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:8900284` (2 mentions) - Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.
  - shared terms: genetic
- `PMID:9140400` (1 mention) - The parentage of a classic wine grape, Cabernet Sauvignon.
  - shared terms: genetic

Weighed against this report's own most characteristic terms: `lqt1`, `jlns1`, `kcnq1`, `cardiac`, `lqts`, `syncope`, `disease`, `exercise`, `variant`, `ecg`, `event`, `genetic`, `drug`, `schwartz`, `risk`, `syndrome`, `lqt2`, `lqt3`, `sudden`, `repolarization`.

All extracted references resolved successfully.
Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 30 |
| Resolved | 29 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 1 |
| Terms whose name was checked | 19 |
| Terms named correctly | 9 |
| Terms named as a **different** term | 4 |
| Terms whose name is worth a second look | 6 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0100316` (2 mentions) - the report calls it "given in the template; confirm the label"; MONDO calls it **long QT syndrome 1**
- `HP:0001279` (1 mention) - the report calls it "Syncope (often exertional or emotion-triggered)"; HP calls it **Syncope**
- `HP:0001250` (1 mention) - the report calls it "Seizure (misdiagnosed arrhythmic syncope)"; HP calls it **Seizure**
- `CHEBI:7445` (1 mention) - the report calls it "Nonselective agents: nadolol"; CHEBI calls it **nafarelin**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0001657` (1 mention) - the report calls it "Prolonged QT interval (QTc often 450–500 ms; broad-based T waves)"; HP calls it **Prolonged QT interval**, and lists "Prolong qt interval on ekg" among its other names
- `HP:0000006` (2 mentions) - the report calls it "Romano-Ward LQT1: autosomal dominant"; HP calls it **Autosomal dominant inheritance**, and lists "Autosomal dominant" among its other names
- `HP:0000007` (1 mention) - the report calls it "JLNS1: autosomal recessive"; HP calls it **Autosomal recessive inheritance**, and lists "Autosomal recessive" among its other names
- `HP:0003829` (1 mention) - the report calls it "Incomplete penetrance"; HP calls it **Typified by incomplete penetrance**, and lists "Incomplete penetrance" among its other names
- `NCIT:C15986` (1 mention) - the report calls it "NCIT: Pharmacotherapy"; NCIT calls it **Pharmacotherapy**
- `NCIT:C15329` (1 mention) - the report calls it "NCIT: Surgical Procedure"; NCIT calls it **Surgical Procedure**

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.